Before we continue, the research project that we’ve completed is opt-in, and we don’t look at anyone’s data without their express permission. We take privacy very seriously, but we also work with an amazing group of founders who are willing to pass on what they’ve learned to the next generation of founders going through the process. If you want to be included in our next round of research, you can find the survey links at the bottom of this blog post.
In a blog post written by Carta CEO Henry Ward, three companies are mentioned: A startup focused on helping other companies come up with fair and market-fitting “total compensation” for employees including both cash and stock; a startup focused on “build[ing] analytic investment tools for venture as an asset class;” and one final startup focused on executing and publishing research on private companies.
Centogene announced this week that its biorepository in Rostock, Germany has received accreditation from the College of American Pathologists (CAP). The CAP's Biorepository Accreditation Program is designed to improve the quality and consistency of biorepositories through requirements for standardization that will result in high-quality human specimens and genetic materials that can be used to support research.
The program will aim to develop and evaluate next-generation genomics and informatics tools to improve the diagnosis, treatment, and prevention of disease. It will leverage available tools and recent research in genomic technologies, computation, and data science, as well as large genomic datasets, DNA from hundreds of thousands of participants collected and stored in biobanks, and electronic health records.
OnRamp Bioinformatics, Inc., a genomics company providing the premier scientist-focused data analysis platform, and Advaita BioInformatics, a leader in personalized medicine and interpretation of Next-Gen Sequencing data, announced they have partnered to provide a comprehensive research experience from sample to interpretation with a seamless hand-off between systems.
As part of an analysis we term “transformatics,” we’ve built the capability to measure the data set we’ve assembled of more than 200 large transformations stretching back nearly a decade. More recently, we isolated the 82 public companies that had undertaken a full-scale transformation and had an observable 18-month transformation track record to see what we could learn from a statistical analysis of their experiences. The research highlighted four indicators that showed a statistically significant correlation with top-quartile financial performance during the 18-month test period (for more about the methodology, see sidebar “Transformatics: Inside the metrics of transformation”). Taken together, the four indicators suggest some potential lessons for senior managers seeking to maximize the odds of a successful transformation. Let’s look at each in turn.